ARCUTIS BIOTHERAPEUTICS INC

Arcutis insider trading shows routine RSU tax moves, not a sell‑off. 1,700 shares sold by CMO Patrick Burnett at $27—no crisis, steady fundamentals and a promising pipeline remain.

Arcutis insider Welgus Howard G. buys shares below market and sells options, signaling confidence in its immunotherapy pipeline and potential upside.

Arcutis insider Patrick Burnett buys shares at $3.64, signaling confidence that the stock is undervalued amid a modest decline and a solid pipeline.

ARCUTIS insider sale: CEO Todd Watanabe sold 4,375 shares on Aug 3, 2026 for $26.12—routine liquidity, not a red flag for investors.

Arcutis Biotherapeutics adds Christopher Peetz to its board, sparking insider buying that signals confidence in its inflammatory skin pipeline and upcoming Q2 earnings.

Arcutis insider buying shows board confidence in its biopharma pipeline—but investors must watch clinical milestones and market reaction.

Arcutis CFO sells 435 shares amid a 10% stock drop; insider selling signals cautious confidence and may signal future restructuring.

Arcutis insider Matsuda Masaru sells 7,372 shares at $23.27, a routine sale amid 2026 liquidity plans; investors note the move’s minimal impact on a 78 % YTD rally and upcoming clinical milestones.

Arcutis Biotherapeutics insider sales show routine tax‑planning, not declining confidence—insiders keep a strong stake while the company’s immune‑disease pipeline drives future growth.

Arcutis insider selling trends: Howard’s 77k-share exit plan and its impact on the stock’s 71% Y/Y rise, valuation, and future buying opportunities.